Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort
- 330 Downloads
Body mass index (BMI), waist-to-hip ratio (WHR), and tumor characteristics affect disease-free survival. Larger breast size may increase breast cancer risk, but its influence on disease-free survival is unclear. The purpose of this study was to elucidate whether breast size independently influenced disease-free survival in breast cancer patients.
Body measurements were obtained preoperatively from 772 breast cancer patients in a population-based ongoing cohort from southern Sweden. The research nurse measured breast volumes with plastic cups used by plastic surgeons doing breast reductions. Clinical data were obtained from patient charts and pathology reports.
Patients with a BMI ≥ 25 kg/m2 had larger tumors (p < 0.001) and more axillary nodal involvement (p = 0.030). Patients with a WHR > 0.85 had larger tumors (p = 0.013), more advanced histological grade (p = 0.0016), and more axillary nodal involvement (p = 0.012). Patients with right + left breast volume ≥ 850 mL were more likely to have larger tumor sizes (p = 0.018), more advanced histological grade (p = 0.031), and more axillary nodal involvement (p = 0.025). There were 62 breast cancer events during the 7-year follow-up. Breast volume ≥ 850 mL was associated with shorter disease-free survival (p = 0.004) and distant metastasis-free survival (p = 0.001) in patients with estrogen receptor (ER)-positive tumors independent of other anthropometric measurements and age. In patients with ER-positive tumors, breast size was an independent predictor of shorter disease-free (HR 3.64; 95 % CI 1.42–9.35) and distant metastasis-free survival (HR 6.33; 95 %CI 1.36–29.43), adjusted for tumor characteristics, BMI, age, and treatment.
A simple and cheap anthropometric measurement with standardized tools may help identify a subgroup of patients in need of tailored breast cancer therapy.
KeywordsBreast cancer Prognosis Body mass index Waist-to-hip ratio Breast size
This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Medical Faculty at Lund University, the Mrs. Berta Kamprad’s Foundation, the Gunnar Nilsson Foundation, the Crafoord Foundation, the Konung Gustaf V Jubileumsfond (104152), the South Swedish Health Care Region (Region Skåne ALF), Swedish Breast Cancer Group (BRO), and the Lund Hospital Fund. We thank our research nurses Linda Ågren, Anette Möller, Karin Henriksson, Anna Weddig, and Maj-Britt Hedenblad. We thank Dr Eric Dryver for proofreading the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.The National Board of Health and Welfare (2010) Cancer incidence in Sweden (Cited May 30, 2012) http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18530/2011-12-15.pdf
- 2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, LyonGoogle Scholar
- 31.Schrauder MG, Fasching PA, Haberle L et al (2011) Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol 137:975–983Google Scholar
- 33.Ringberg A, Bågeman E, Rose C, Ingvar C, Jernström H (2006) Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 119: 2242–2243; Author reply 4Google Scholar
- 35.(2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 894:i–xii, 1–253Google Scholar
- 37.Jernström H, Sandberg T, Bågeman E, Borg Å, Olsson H (2005) Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 92:857–866PubMedCrossRefGoogle Scholar